Literature DB >> 25849048

Quantitative profiling of brain lipid raft proteome in a mouse model of fragile X syndrome.

Magdalena Kalinowska1, Catherine Castillo1, Anna Francesconi1.   

Abstract

Fragile X Syndrome, a leading cause of inherited intellectual disability and autism, arises from transcriptional silencing of the FMR1 gene encoding an RNA-binding protein, Fragile X Mental Retardation Protein (FMRP). FMRP can regulate the expression of approximately 4% of brain transcripts through its role in regulation of mRNA transport, stability and translation, thus providing a molecular rationale for its potential pleiotropic effects on neuronal and brain circuitry function. Several intracellular signaling pathways are dysregulated in the absence of FMRP suggesting that cellular deficits may be broad and could result in homeostatic changes. Lipid rafts are specialized regions of the plasma membrane, enriched in cholesterol and glycosphingolipids, involved in regulation of intracellular signaling. Among transcripts targeted by FMRP, a subset encodes proteins involved in lipid biosynthesis and homeostasis, dysregulation of which could affect the integrity and function of lipid rafts. Using a quantitative mass spectrometry-based approach we analyzed the lipid raft proteome of Fmr1 knockout mice, an animal model of Fragile X syndrome, and identified candidate proteins that are differentially represented in Fmr1 knockout mice lipid rafts. Furthermore, network analysis of these candidate proteins reveals connectivity between them and predicts functional connectivity with genes encoding components of myelin sheath, axonal processes and growth cones. Our findings provide insight to aid identification of molecular and cellular dysfunctions arising from Fmr1 silencing and for uncovering shared pathologies between Fragile X syndrome and other autism spectrum disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25849048      PMCID: PMC4388542          DOI: 10.1371/journal.pone.0121464

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Genetic studies have uncovered hundreds of candidate loci [1, 2] associated with Autism Spectrum Disorders (ASDs). Despite remarkable progress, one major outstanding challenge is identification of shared biological pathways that could contribute to convergent dysfunctions arising from genetic heterogeneity [3, 4]. Fragile X syndrome (FXS), a leading cause of inherited intellectual disability, accounts for 2–5% of autism cases and ~30% of individuals with FXS are diagnosed with autism, suggesting that the conditions may share common pathophysiology [5, 6]. FXS is a monogenic disorder that arises from abnormal expansion of a tri-nucleotide repeat in the 5’-untranslated region of the X-linked Fmr1 gene, leading to transcriptional silencing that results in loss of Fragile X Mental Retardation Protein (FMRP) expression [7]. FMRP is an RNA-binding protein that binds to >4% of brain transcripts [8, 9] to regulate mRNA translation, trafficking and stability [7, 10–12]. FMRP was shown to inhibit mRNA translation [7] and in its absence basal protein synthesis is abnormally elevated [13, 14]. Profound abnormalities in intracellular signaling pathways have also been observed in cells lacking FMRP. Cyclic AMP production is decreased [15, 16] whereas basal activities of Ras [17], extracellular signal-regulated protein kinases 1/2 (ERK1/2; [18, 19]), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K; [20, 21]) and mammalian target of rapamycin (mTOR [22, 23]) are abnormally enhanced. In contrast, receptor dependent signaling is impaired including signaling by group 1 metabotropic glutamate receptors (Gp1 mGluRs) to ERK1/2 [19] and PI3K-AKT-mTOR [22, 24] pathways and signaling by dopamine receptor 1 (D1R) to the cAMP cascade [25]. Collectively, these findings suggest that loss of FMRP leads to general deficits in the efficiency and regulation of cellular signaling, dysfunctions that might be common to other disorders in the autism spectrum. Lipid rafts (also termed membrane rafts) are liquid-ordered regions of the plasma membrane, originating from local enrichment in glycosphingolipids and cholesterol, that recruit selected integral membrane proteins and proteins carrying glycosylphosphatidylinositol (GPI) anchors: in addition, palmitoylated and acylated proteins associate with the inner leaflet of plasma membrane rafts [26, 27]. Lipid rafts are thought to provide transient ‘platforms’ for receptors and signaling effectors thereby contributing to regulation of cell signaling [28, 29]. Native lipid rafts are plastic, transient, small (~40–100 nm) membrane subdomains that are not amenable to biochemical purification; description of their putative composition as well as identification of properties shared by proteins endowed with raft affinity have largely originated from the characterization of detergent-resistant membranes (DRMs). DRMs are a collection of buoyant membranes resistant to solubilization by cold, non-ionic detergents and are selectively enriched in cholesterol, glycolipids and raft-associated proteins [30]. Importantly, DRMs are amenable to biochemical purification and thus afford a means of assessment of lipid raft composition under basal and perturbed conditions [31]. In the central nervous system (CNS), lipid rafts have been implicated in establishment of neuron polarity [32, 33], axon guidance [34], dendritogenesis [35], spine morphogenesis [36] and myelination [37, 38]. Lipid raft composition is remodeled during neuronal differentiation [34] and aging [39], and is altered in neuropsychiatric conditions [40] including Alzheimer’s disease [41], schizophrenia [42], depression [43] and Smith-Lemli-Opitz syndrome [44]—an autism spectrum disorder [45, 46]. Despite the broad impact of Fmr1 ablation on neuronal signaling, it remains unknown whether the composition of lipid rafts is altered in animal models of FXS. A subset of RNA transcripts predicted to bind FMRP [8] encodes proteins critically involved in lipid synthesis and transport: thus, loss of FMRP expression may conceivably affect lipid homeostasis and lipid raft properties. To examine whether loss of FMRP expression results in alterations in the properties of lipid rafts, we used a systems biology approach based on protein identification and quantification by mass spectrometry. We used isobaric tags for relative and absolute quantification (iTRAQ; [47]) to label peptides for qualitative and quantitative analysis of the proteome of DRMs purified from mouse brain. By this strategy we uncovered candidate proteins that are differentially represented in the lipid raft proteome of FMR1 knockout mice and linked them by network analysis to specific cellular components and functional pathways, such as axonal processes and myelination, which could be affected by ablation or silencing of Fmr1.

Materials and Methods

Reagents and animals

The following antibodies were used according to manufacturer recommendations: mouse monoclonal antibodies anti-Flotilllin-1 (BD Biosciences), anti-Homer1b/c (Santa Cruz Biotechnology), anti-Ly6h (Abnova) anti-Plp1 (Millipore), anti-Thy-1 (BioLegend), anti-Transferrin receptor 1 (Invitrogen), anti-β-Tubulin (Sigma Aldrich), anti-γ-Tubulin (Sigma Aldrich) and rabbit polyclonal antibodies anti-CaMKIIα/β Cell Signaling Technology) and anti-Gnb2 (Abcam). Mouse anti-Versican core protein (clone 351/24) was obtained from the UC Davis/NIH NeuroMab Facility. Wild type and Fmr1 null (FVB.129P2-Pde6b strain) mice were obtained from The Jackson Laboratories (Bar Harbor, ME) and bred in house. For euthanasia, mice were deeply anesthetized by isoflurane inhalation until insensate and decapitated. All animal procedures were carried out according to protocols approved by the Albert Einstein College of Medicine Institutional Animal Care and Use Committee and in accordance with the Guide for the Care and Use of Laboratory Animals by the United States Public Health Service.

Subcellular fractionation and western blot

Cortices (hippocampi removed), hippocampi and cerebella from adult WT and Fmr1 KO mice (~ five month-old) were homogenized on ice in homogenization buffer of 10 mM Tris-HCl pH 7.4, 5 mM EDTA, 320 mM sucrose, eukaryotic protease inhibitor cocktail and Na3VO4. Homogenates were centrifuged for 10 min at 800 x g to precipitate nuclei and supernatant fraction collected (S1) and centrifuged at 10,000 x g for 15 min. The resulting pellet (P2) and supernatant (S2) were separated and solubilized in lysis buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% CHAPS supplemented with protease inhibitor cocktail and Na3VO4. Analysis of proteins was performed by protein separation by SDS-PAGE followed by immunoblot with specific primary antibodies and detection with horseradish peroxidase-conjugated secondary antibodies as previously described [48].

Isolation of detergent resistant membranes (DRM) from mouse brain tissue

DRM preparation was carried out according to previously described procedures [49]. Briefly, adult mice (~ five to six month-old) were euthanized and microdissected tissue rinsed with saline solution and homogenized with a Dounce tissue grinder in cold homogenization buffer with protease inhibitors. After low speed centrifugation to remove nuclei and residual particulate material, supernatants were spun at 10,000 x g at 4ºC and resulting pellets dissolved in cold buffer of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100 (v/v) and incubated on ice (10 min). Solubilized pellets were adjusted to 40% sucrose and fractionated on discontinuous sucrose gradients by centrifugation at 34,000 rpm (SW40 Ti; Beckman Coulter) for 16 h. Thirteen fractions (1 ml each) were collected from each gradient starting from the top and an aliquot of each analyzed by Western blot.

iTRAQ proteomics

We carried out proteomic profiling of WT and Fmr1 KO mice using purified DRMs labeled with iTRAQ reagents: samples were processed by Applied Biomics (Hayward, CA) for isotope labeling and analytical mass spectrometry. Briefly, DRMs were purified from freshly dissected cortices (hippocampi removed) from individual mice (three animals per genotype in one experiment and two animals per genotype in two experiments): fractions enriched in DRMs (routinely fractions # 3, 4, and 5) were combined for each genotype to yield approximately 6 or 9 ml collective volume, depending on number of animals, and concentrated. Equal amounts of protein for WT and Fmr1 KO mice, approximately 6 to 8 μg depending on the preparation, were reduced and alkylated followed by digestion with trypsin and labeling with iTRAQ reagents (AB Sciex) with reporter ions/isobaric tags 114/113 or 118/117. Tagged peptides were combined and fractionated on a nano-LC column and analyzed by MS and MS/MS with ABSCIEX 5800 (AB Sciex). For protein identification, MS/MS spectra were submitted for search of the SwissProt and decoy databases using MASCOT. For each protein hit, only peptides with a confidence interval (C.I.) >95% were considered. Peptides corresponding to keratin, a potential contaminant, were excluded from final combined analysis of independent experiments. The ratios of peptide quantities expressed as signal intensity ratios of reporter groups for individual peaks were obtained to calculate average ratio(s) for the protein, number of peptides that contributed to the average and the geometric standard deviation. In some instances, a ratio could not be determined because one or more relevant peaks were missing or peptide match was rejected based on confidence interval.

Gene ontology enrichment and protein interaction network analyses

Gene ontology (GO) analysis was carried out with the Database for Annotation, Visualization and Integrated Discovery (DAVID; [50, 51]). The database was searched using a subset of the brain raft proteome that included 85 genes encoding proteins for which comparative quantitative information was obtained, and used to assess enrichment in particular GO terms. Identified GO terms were grouped based on functional annotation for biological process (GO_BP), cellular component (GO_CC), and molecular function (GO_MF). Functional annotation was carried out according to published protocols [50] with default settings and using Mus musculus genome as background reference database. Terms with Benjamini Hochberg-corrected p value <0.05 are illustrated. Network analysis was carried out using a query list of four genes encoding proteins that showed differential abundance in the brain raft proteome of Fmr1 KO mice using Mus musculus as reference. The query list did not include Tubb2a and Tubb5, encoding tubulin isoforms, to prevent skewing the network and Ly6h due to paucity of information for this gene. Analysis and representation of network connections were carried out with GeneMANIA [52] with default settings: predicted connectivity is illustrated by links which reflect degree of confidence of relationships between gene pairs.

Results

Characterization of mouse brain lipid raft proteome

In neurons, lipid rafts recruit ion channels and ionotropic neurotransmitter receptors, including glutamate and nicotinic acetylcholine receptors, and regulate the activity of metabotropic receptors for neurotransmitters and neuromodulators [53]. In Fmr1 null neurons, tonic activity of selected signaling effector proteins and metabotropic functions of Gp1 mGluRs, dopamine and cannabinoid [54] receptors among others are dysregulated, but whether the integrity and/or function of lipid rafts are compromised in absence of FMRP is unknown. Here, we set out to determine whether the relative abundance of proteins associated with raft membranes is altered by potential homeostatic changes occurring upon loss of FMRP expression. To examine whether the composition of the brain lipid raft proteome is altered in absence of FMRP, we used a well-characterized animal model of FXS—Fmr1 knockout mice (Fmr1 KO; [55]). To this end, we isolated detergent-resistant membranes (DRMs; [49]) from the cerebrum of adult wild type (WT) and mutant Fmr1 knockout (Fmr1 KO) mice to recover sufficient material for proteome analysis. We used anti-Flotillin-1 antibodies to identify membrane fractions enriched with lipid rafts and anti-Transferrin receptor 1 (TfR1) antibodies to visualize gradient fractions containing non-raft membranes. Flotillin-1 is abundantly expressed in the brain and its selective association with raft membranes has been extensively characterized in both primary neurons and brain tissue [56] and thus represents a reliable marker of lipid raft enrichment. In contrast, TfR1 is excluded from lipid raft membranes under resting or stimulated conditions [57] in both primary cells and native tissue and thus affords a reliable indicator of non-raft membranes. We found Flotillin-1 to be consistently enriched in three buoyant gradient fractions (fractions 3 to 5; Fig 1A) in both mutant and wild type mouse brain whereas TfR1 appeared concentrated in heavy gradient fractions and virtually absent from buoyant, lipid raft enriched membranes (Fig 1B). Together, these observations indicate that DRMs purified from both Fmr1 KO and WT mouse cerebrum are overall enriched in lipid raft-associated proteins and not significantly contaminated by non-raft membranes, thus providing material of adequate purity for interrogation of the lipid raft proteome.
Fig 1

Purification of lipid raft enriched membranes from wild type and Fmr1 mutant mouse brain.

A) Schematic of isopycnic sucrose gradient used in isolation procedure of detergent resistant membranes (DRMs). Light gradient fractions containing DRMs (fractions 3 to 5) and heavy gradient fractions containing non-raft proteins are indicated. B) Representative immunoblots of extracts from WT and Fmr1 KO mouse brain illustrating isolation of DRMs used for proteomic studies. Numbers above gel lanes indicate gradient fractions (#1, first fraction; #13, bottom gradient fraction). Input, total homogenate; Flot-1, Flotillin-1; TfR1, Transferrin receptor 1; IB, immunoblot.

Purification of lipid raft enriched membranes from wild type and Fmr1 mutant mouse brain.

A) Schematic of isopycnic sucrose gradient used in isolation procedure of detergent resistant membranes (DRMs). Light gradient fractions containing DRMs (fractions 3 to 5) and heavy gradient fractions containing non-raft proteins are indicated. B) Representative immunoblots of extracts from WT and Fmr1 KO mouse brain illustrating isolation of DRMs used for proteomic studies. Numbers above gel lanes indicate gradient fractions (#1, first fraction; #13, bottom gradient fraction). Input, total homogenate; Flot-1, Flotillin-1; TfR1, Transferrin receptor 1; IB, immunoblot. To systematically investigate the composition of the lipid raft proteome in Fmr1 KO mice and quantitatively compare the relative abundance of raft-associated proteins to WT mice, we used isobaric tags for relative and absolute quantification (iTRAQ; [47])-based mass spectrometry (Fig 2). We chose iTRAQ because it affords concurrent identification and quantification of peptides in complex mixtures in solution and can be applied to purified sub-cellular fractions. Moreover, iTRAQ does not require gel matrix-based protein isolation that may compromise recovery of integral membrane proteins and hydrophobic polypeptides. Peptides differentially labeled with iTRAQ tags are chromatographically indistinguishable due to mass conservation but when fragmented by tandem mass-spectrometry analysis a balance group is released and unmasked reporter ions allow relative quantification of peaks in mass spectra.
Fig 2

Workflow of iTRAQ proteomic strategy.

Illustration of principal steps for qualitative and quantitative proteomic profiling of brain DRMs.

Workflow of iTRAQ proteomic strategy.

Illustration of principal steps for qualitative and quantitative proteomic profiling of brain DRMs. To implement iTRAQ workflow (Fig 2), DRM-containing gradient fractions were pooled to obtain sufficient material while decreasing individual variability: proteolytic peptides of mutant or wild type DRMs were independently labeled with different iTRAQ tags and then combined into one sample mixture that was analyzed by MS/MS. Three independent experiments were performed with mice from different litters: obtained peptide matches above identity threshold were 575 (FDR 1.22%), 796 (FDR 1.63%) and 257 (FDR 0.00%), respectively. High-confidence peptides for either genotypes identified 201, 293 and 140 protein hits from individual experiments, in good agreement with estimated raft proteome complexity of ~ 200 proteins [58, 59]. For data analysis, we combined independently obtained 2-plex datasets and compiled a list of 133 candidate proteins present in brain lipid rafts (Table 1) that includes proteins identified in both genotypes by high confidence peptides in at least one experiment (S1 Table). Overall, the derived representation of the mouse brain lipid raft proteome is concordant with proteomic studies previously performed employing alternative strategies [39, 58, 60–62] or tissue samples including neonatal mouse brain [58] and human brain tissue [62]. To evaluate the functions associated with proteins present in the lipid raft proteome of adult mouse brain, high confidence raft proteins identified in all three experiments (85 proteins; Table 2) were used to search the Database for Annotation, Visualization and Integrated Discovery (DAVID; [50, 51]) that allows identification of over-represented Gene Ontology (GO) terms in query protein/gene sets. Bioinformatics analysis with DAVID revealed that proteins present in brain lipid rafts were mostly associated with plasma membrane as expected (Table 3) but also enriched at synapses and cell projections and significantly associated with heterotrimeric G protein complexes. Molecular functions (Table 3) over-represented in the lipid raft proteome included ion and proton transport, ATPase and GTPase activity and component of myelin sheath. Moreover, brain lipid raft proteins appeared to be significantly associated with important biological processes (Table 3) involved in neuronal function and maturation including, but not limited to, synaptic transmission and cell adhesion.
Table 1

Lipid raft proteome of adult mouse brain.

#UniProtKBGene symbolGene IDDescription***^^^#
1 1433BYwhab5440114-3-3 protein beta/alpha
2 1433EYwhae2262714-3-3 protein epsilon
3 1433GYwhag2262814-3-3 protein gamma
4 1433ZYwhaz2263114-3-3 protein zeta/delta
5 AATMGot214719Aspartate aminotransferase, mitochondrial
6 ACTBActb11461Actin, cytoplasmic 1
7 ACTCActc111464Actin, alpha cardiac muscle 1
8 ACTN1Actn1109711Actinin-1
9 ACTN2Actn211472Actinin-2
10 ADT1Slc25a411739ADP/ATP translocase 1
11 ADT2Slc25a511740ADP/ATP translocase 2
12 AGKAgk69923Acylglycerol kinase, mitochondrial
13 AINXIna226180Alpha-internexin
14 ALDOAAldoa11674Fructose-bisphosphate aldolase A
15 ANS1BAnks1b77531Ankyrin repeat and sterile alpha motif domain-containing protein 1B
16 AT1A1Atp1a111928Na/K-transporting ATPase subunit alpha-1
17 AT1A3Atp1a3232975Na/K-transporting ATPase subunit alpha-3
18 AT1B1Atp1b111931Sodium/potassium-transporting ATPase subunit beta-1
19 ATPAAtp5a111946ATP synthase subunit alpha, mitochondrial
20 ATPBAtp5b11947ATP synthase subunit beta, mitochondrial
21 BAIP2Baiap2108100Brain-specific angiogenesis inhibitor 1-assoc. protein 2
22 BASP1Basp170350Brain acid soluble protein 1
23 BSNBsn12217Protein bassoon
24 C1QBPC1qbp12261Complement component 1 Q subcomponent-binding protein (mito)
25 CA2D1Cacna2d112293Voltage-dependent Ca channel subunit alpha-2/delta-1
26 CA2D2Cacna2d256808Voltage-dependent Ca channel subunit alpha-2/delta-2
27 CA2D3Cacna2d312294Voltage-dependent Ca channel subunit alpha-2/delta-3
28 CAD13Cdh1312554Cadherin-13
29 CALMCalm112313Calmodulin
30 CLCBCltb74325Clathrin light chain B
31 CLCN6Clcn626372Chloride transport protein 6
32 CLD11Cldn1118417Claudin-11
33 CLH1Cltc67300Clathrin heavy chain 1
34 CMC1Slc25a1278830Calcium-binding mitochondrial carrier protein Aralar1
35 CN37Cnp127992',3'-cyclic-nucleotide 3'-phosphodiesterase
36 CNTN1Cntn112805Contactin-1
37 CNTN2Cntn221367Contactin-2
38 CNTP1Cntnap153321Contactin-associated protein 1
39 COX2Mtco217709Cytochrome c oxidase subunit 2
40 COX5ACox5a12858Cytochrome c oxidase subunit 5A, mitochondrial
41 CSPG2Vcan13003Versican core protein
42 CTNA2Ctnna212386Catenin alpha-2
43 DLG4Dlg413385Disks large homolog 4
44 DLGP3Dlgap3242667Disks large-associated protein 3
45 DPYL2Dpysl212934Dihydropyrimidinase-related protein 2
46 DYL1Dynll156455Dynein light chain 1, cytoplasmic
47 ENPP6Enpp6320981Ectonucleotide pyrophosphatase/phosphodiesterase member 6
48 ERC2Erc2238988ERC protein 2
49 FLOT1Flot114251Flotillin-1
50 FLOT2Flot214252Flotillin-2
51 G3PGapdh14433Glyceraldehyde-3-phosphate dehydrogenase
52 GBB1Gnb114688Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
53 GBG12Gng1214701Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma12
54 GBG2Gng214702Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma2
55 GNAI1Gnai114677Guanine nucleotide-binding protein G(i) subunit alpha1
56 GNAI2Gnai214678Guanine nucleotide-binding protein G(i) subunit alpha2
57 GNAOGnao114681Guanine nucleotide-binding protein G(o) subunit alpha
58 GNAS1Gnas14683Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas
59 GNAZGnaz14687Guanine nucleotide-binding protein G(z) subunit alpha
60 HOME1Homer126556Homer protein homolog 1
61 HPLN1Hapln112950Hyaluronan and proteoglycan link protein 1
62 HPLN2Hapln273940Hyaluronan and proteoglycan link protein 2
63 HS71LHspa1l15482Heat shock 70 kDa protein 1-like
64 HSP7CHspa815481Heat shock cognate 71 kDa protein
65 HXK1Hk115275Hexokinase-1
66 IGS21Igsf21230868Immunoglobulin superfamily member 21
67 IQEC1Iqsec1232227IQ motif and SEC7 domain-containing protein 1
68 IQEC2Iqsec2245666IQ motif and SEC7 domain-containing protein 2
69 KCC2ACamk2a12322Ca/calmodulin-dependent protein kinase type II α sub.
70 KCC2BCamk2b12323Ca/calmodulin-dependent protein kinase type II β sub.
71 KCC2DCamk2d108058Ca/calmodulin-dependent protein kinase type II δ sub.
72 KCC2GCamk2g12325Ca/calmodulin-dependent protein kinase type II γ sub.
73 KCRBCkb12709Creatine kinase B-type
74 LSAMPLsamp268890Limbic system-associated membrane protein
75 LY6HLy6h23934Lymphocyte antigen 6H
76 MAP1AMap1a17754Microtubule-associated protein 1A
77 MBPMbp17196Myelin basic protein
78 MDHMMdh217448Malate dehydrogenase, mitochondrial
79 ML12BMyl12b67938Myosin regulatory light chain 12B
80 MOBPMobp17433Myelin-associated oligodendrocyte basic protein
81 MOGMog17441Myelin-oligodendrocyte glycoprotein
82 MYH10Myh1077579Myosin-10
83 MYH9Myh917886Myosin-9
84 MYL6Myl617904Myosin light polypeptide 6
85 MYO5AMyo5a17918Unconventional myosin-Va
86 MYPRPlp118823Myelin proteolipid protein
87 NCAM1Ncam117967Neural cell adhesion molecule 1
88 NCANNcan13004Neurocan core protein
89 NDUA4Ndufa417992NADH dehydrogenase 1 alpha subcomplex sub. 4
90 NEGR1Negr1320840Neuronal growth regulator 1
91 NEUMGap4314432Neuromodulin
92 NFLNefl18039Neurofilament light polypeptide
93 NFMNefm18040Neurofilament medium polypeptide
94 NTRINtm235106Neurotrimin
95 ODO2Dlst78920Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex (mito)
96 ODP2Dlat235339Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex (mito)
97 OMGPOmg18377Oligodendrocyte-myelin glycoprotein
98 PCLOPclo26875Protein piccolo
99 PRIOPrnp19122Major prion protein
100 RAC1Rac119353Ras-related C3 botulinum toxin substrate 1
101 SCAIScai320271Protein SCAI
102 SEPT7Sept7235072Septin-7
103 SHAN3Shank358234SH3 and multiple ankyrin repeat domains protein 3
104 SNP25Snap2520614Synaptosomal-associated protein 25
105 SPTA2Sptan120740Spectrin alpha chain, brain
106 SPTB2Sptbn120742Spectrin beta chain, brain 1
107 STX1BStx1b56216Syntaxin-1B
108 SYGP1Syngap1240057Ras GTPase-activating protein SynGAP
109 SYPHSyp20977Synaptophysin
110 SYT1Syt120979Synaptotagmin-1
111 SYT2Syt220980Synaptotagmin-2
112 TBA1ATuba1a22142Tubulin alpha-1A chain
113 TBA1BTuba1b22143Tubulin alpha-1B chain
114 TBA3Tuba3a22144Tubulin alpha-3 chain
115 TBA4ATuba4a22145Tubulin alpha-4A chain
116 TBB2ATubb2a22151Tubulin beta-2A chain
117 TBB3Tubb322152Tubulin beta-3 chain
118 TBB4ATubb4a22153Tubulin beta-4A chain
119 TBB4BTubb4b227613Tubulin beta-4B chain
120 TBB5Tubb522154Tubulin beta-5 chain
121 THY1Thy121838Thy-1 membrane glycoprotein
122 TPM3Tpm359069Tropomyosin alpha-3 chain
123 VA0D1Atp6v0d111972V-type proton ATPase subunit d 1
124 VAMP2Vamp222318Vesicle-associated membrane protein 2
125 VATAAtp6v1a11964V-type proton ATPase catalytic subunit A
126 VATB2Atp6v1b211966V-type proton ATPase subunit B, brain isoform
127 VATC1Atp6v1c166335V-type proton ATPase subunit C 1
128 VATDAtp6v1d73834V-type proton ATPase subunit D
129 VATE1Atp6v1e111973V-type proton ATPase subunit E 1
130 VATFAtp6v1f66144V-type proton ATPase subunit F
131 VATG2Atp6v1g266237V-type proton ATPase subunit G 2
132 VDAC1Vdac122333Voltage-dependent anion-selective channel protein 1
133 VPP1Atp6v0a111975V-type proton ATPase 116 kDa subunit a isoform 1

(√), Identified in corresponding proteomic studies: * [58], ** [61], ^ [62], ^^ [60], # [39]. List of all proteins (133) identified in DRMs from adult WT and Fmr1 KO mouse brain. List includes proteins identified in three, two or one experiment. Entry descriptors: UniProtKB, UniProt Knowledgebase database (UniProtKB/Swiss-Prot) Mus musculus protein entry name; gene symbol, Mus musculus; Entrez Gene ID, National Center for Biotechnology Information (NCBI) Entrez Mus musculus gene ID. Columns annotated with symbols (*, **, ^, ^^, #) correspond to proteomic studies listed in appended references that reported identification of the corresponding protein in lipid rafts.

Table 2

Quantitative profiling of lipid raft proteome in WT and Fmr1 KO mouse brain.

#UniProtKBGene symbolEntrez IDAve KO/WTSdev P-value Description
11433BYwhab544010.990.3750.909ns14-3-3 protein beta/alpha
2AATMGot2147191.070.5370.865nsAspartate aminotransferase, mitochondrial
3ACTBActb114610.970.1100.560nsActin, cytoplasmic 1
4ACTCActc1114640.990.1240.758nsActin, alpha cardiac muscle 1
5ADT1Slc25a4117390.900.2400.485nsADP/ATP translocase 1
6ADT2Slc25a5117400.950.2540.712nsADP/ATP translocase 2
7ANS1BAnks1b775311.050.0990.588nsAnkyrin repeat and sterile alpha motif domain-containing protein 1B
8AT1A3Atp1a32329751.080.0210.180nsSodium/potassium-transporting ATPase subunit alpha-3
9AT1B1Atp1b1119311.220.6010.591nsSodium/potassium-transporting ATPase subunit beta-1
10ATPAAtp5a1119460.920.1210.304nsATP synthase subunit alpha, mitochondrial
11ATPBAtp5b119470.910.1640.366nsATP synthase subunit beta, mitochondrial
12BAIP2Baiap21081001.290.3350.237nsBrain-specific angiogenesis inhibitor 1-associated protein 2
13BASP1Basp1703501.130.0700.101nsBrain acid soluble protein 1
14BSNBsn122171.130.1120.204nsProtein bassoon
15C1QBPC1qbp122610.990.2170.886nsComplement component 1 Q subcomponent-binding protein, (mito)
16CA2D1Cacna2d1122930.990.1110.736nsVoltage-dependent calcium channel subunit alpha-2/delta-1
17CA2D3Cacna2d3122940.790.1370.065nsVoltage-dependent calcium channel subunit alpha-2/delta-3
18CAD13Cdh13125540.930.1300.376nsCadherin-13
19CALMCalm1123130.850.1690.186nsCalmodulin
20CLH1Cltc673000.920.2050.479nsClathrin heavy chain 1
21CN37Cnp127991.320.2440.101ns2',3'-cyclic-nucleotide 3'-phosphodiesterase
22CNTN1Cntn1128050.890.1250.203nsContactin-1
23CNTN2Cntn2213670.880.2220.363nsContactin-2
24COX2Mtco2177091.040.1580.776nsCytochrome c oxidase subunit 2
25COX5ACox5a128581.020.4910.974nsCytochrome c oxidase subunit 5A, mitochondrial
26 CSPG2 Vcan 13003 0.82 0.079 0.031 * Versican core protein
27DLG4Dlg4133850.940.2360.631nsDisks large homolog 4
28ENPP6Enpp63209811.220.3400.366nsEctonucleotide pyrophosphatase/phosphodiesterase 6
29 ERC2 Erc2 238988 1.17 0.066 0.042 * ERC protein 2
30FLOT1Flot1142510.800.1460.084nsFlotillin-1
31FLOT2Flot2142521.100.1010.280nsFlotillin-2
32GBB1Gnb1146880.760.2640.186nsGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
33GBG12Gng12147011.290.8600.608nsGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12
34GBG2Gng2147021.280.2260.121nsGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
35GNAOGnao1146811.190.2290.259nsGuanine nucleotide-binding protein G(o) subunit alpha
36GNAS1Gnas146831.140.3610.581nsGuanine nucleotide-binding protein G(s) subunit alpha isoforms XLas
37GNAZGnaz146871.120.2510.516nsGuanine nucleotide-binding protein G(z) subunit alpha
38HOME1Homer1265561.310.2800.148nsHomer protein homolog 1
39HSP7CHspa8154811.010.064>0.999nsHeat shock cognate 71 kDa protein
40IGS21Igsf212308681.010.0830.918nsImmunoglobulin superfamily member 21
41KCC2ACamk2a123221.270.2990.215nsCalcium/calmodulin-dependent protein kinase type II subunit alpha
42KCC2BCamk2b123231.240.3650.343nsCalcium/calmodulin-dependent protein kinase type II subunit beta
43KCC2GCamk2g123251.210.3310.362nsCalcium/calmodulin-dependent protein kinase type II subunit gamma
44KCRBCkb127090.850.1240.108nsCreatine kinase B-type
45LSAMPLsamp2688900.940.1420.443nsLimbic system-associated membrane protein
46 LY6H Ly6h 23934 0.76 0.020 0.003 ** Lymphocyte antigen 6H
47MAP1AMap1a177541.060.0970.499nsMicrotubule-associated protein 1A
48MBPMbp171961.350.3180.144nsMyelin basic protein
49MDHMMdh2174480.850.3270.444nsMalate dehydrogenase, mitochondrial
50MOBPMobp174331.470.3450.089nsMyelin-associated oligodendrocyte basic protein
51MOGMog174411.310.1850.060nsMyelin-oligodendrocyte glycoprotein
52MYH10Myh10775791.020.2450.966nsMyosin-10
53MYH9Myh9178861.140.6680.760nsMyosin-9
54MYO5AMyo5a179181.050.1360.720nsUnconventional myosin-Va
55 MYPR Plp1 18823 1.55 0.176 0.008 ** Myelin proteolipid protein
56NCAM1Ncam1179671.000.1280.880nsNeural cell adhesion molecule 1
57NCANNcan130041.020.4270.990nsNeurocan core protein
58NEGR1Negr13208401.010.2090.980nsNeuronal growth regulator 1
59NTRINtm2351060.970.1010.566nsNeurotrimin
60ODO2Dlst789201.150.2670.448nsDihydrolipoyllysine succinyltransferase comp. of 2-oxoglutarate dehydrogenase complex
61ODP2Dlat2353391.030.1500.894nsDihydrolipoyllysine acetyltransferase comp. of pyruvate dehydrogenase complex
62OMGPOmg183771.120.0440.076nsOligodendrocyte-myelin glycoprotein
63PCLOPclo268751.080.0150.140nsProtein piccolo
64PRIOPrnp191220.840.1420.126nsMajor prion protein
65RAC1Rac1193531.280.3810.293nsRas-related C3 botulinum toxin substrate 1
66SCAIScai3202711.460.9710.471nsProtein SCAI
677-SepSept72350721.450.2720.052nsSeptin-7
68SHAN3Shank3582341.010.2840.970nsSH3 and multiple ankyrin repeat domains protein 3
69SNP25Snap25206141.100.5510.800nsSynaptosomal-associated protein 25
70SPTA2Sptan1207400.970.1570.681nsSpectrin alpha chain, brain
71SPTB2Sptbn1207420.970.0990.530nsSpectrin beta chain, brain 1
72STX1BStx1b562161.050.4450.895nsSyntaxin-1B
73SYGP1Syngap12400571.090.1060.344nsRas GTPase-activating protein SynGAP
74SYT1Syt1209790.900.2360.456nsSynaptotagmin-1
75TBA1BTuba1b221431.210.1550.113nsTubulin alpha-1B chain
76 TBB2A Tubb2a 22151 1.29 0.155 0.045 * Tubulin beta-2A chain
77 TBB5 Tubb5 22154 1.27 0.125 0.034 * Tubulin beta-5 chain
78 THY1 Thy1 21838 0.66 0.132 0.014 * Thy-1 membrane glycoprotein
79VA0D1Atp6v0d1119721.270.2550.163nsV-type proton ATPase subunit d 1
80VAMP2Vamp2223181.120.7150.810nsVesicle-associated membrane protein 2
81VATAAtp6v1a119641.050.1370.697nsV-type proton ATPase catalytic subunit A
82VATB2Atp6v1b2119661.040.0900.662nsV-type proton ATPase subunit B, brain isoform
83VATE1Atp6v1e1119731.170.2320.314nsV-type proton ATPase subunit E 1
84VDAC1Vdac1223331.000.3670.954nsVoltage-dependent anion-selective channel protein 1
85VPP1Atp6v0a1119751.190.1560.144nsV-type proton ATPase 116 kDa subunit a isoform 1

List of proteins (85) identified and quantified in three independent experiments in WT and Fmr1 KO brain DRMs. Numbers highlighted in bold correspond to proteins with significantly different abundance in FMR1 KO rafts. Indicated are mean ratio of Fmr1 KO vs. WT (KO/WT), standard deviation (Sdev) and p-value (t-test) in relation to internal reference (HSP7C, mean ± sdev, 1.01 ± 0.064), with p <0.05 considered significant. Entry descriptors: UniProtKB, UniProt Knowledgebase database (UniProtKB/Swiss-Prot) Mus musculus protein entry name; gene symbol, Mus musculus; Entrez Gene ID, National Center for Biotechnology Information (NCBI) Entrez Mus musculus gene ID.

Table 3

Gene ontology annotation of brain lipid raft proteome.

GOTERM _CCTermCount%P valueFold enrich.BonferroniBenjamini
GO:0005886Plasma membrane4856.475.34E-112.451.09E-081.09E-08
GO:0031225Anchored to membrane1416.479.19E-1010.071.88E-079.37E-08
GO:0045202Synapse1315.291.18E-066.072.41E-043.44E-05
GO:0005834Heterotrimeric G-protein complex67.063.17E-0625.526.46E-048.08E-05
GO:0042995Cell projection1618.824.84E-064.149.87E-049.87E-05
GOTERM _MF Term
GO:0015077Monovalent inorganic cation transmembrane transporter activity1011.764.54E-1022.467.77E-087.77E-08
GO:0005516Calmodulin binding1011.765.16E-0917.148.82E-074.41E-07
GO:0015078Hydrogen ion transmembrane transporter activity910.597.21E-0921.451.23E-064.11E-07
GO:0042625ATPase activity, coupled to transmembrane movement of ions89.415.06E-0822.668.66E-061.73E-06
GO:0003924GTPase activity910.592.41E-0713.744.12E-055.89E-06
GO:0016887ATPase activity1112.941.31E-067.652.23E-041.86E-05
GO:0019911Structural constituent of myelin sheath33.57.49E-05195.410.01278.53E-04
GOTERM _BP Term
GO:0006754ATP biosynthetic process910.591.21E-0820.159.99E-069.99E-06
GO:0019226Transmission of nerve impulse1214.123.04E-089.752.50E-058.33E-06
GO:0015985Energy coupled proton transport, down electrochemical gradient78.243.97E-0834.743.27E-054.67E-06
GO:0007268Synaptic transmission1011.764.38E-0710.323.60E-041.80E-05
GO:0006119Oxidative phosphorylation78.245.12E-0722.954.21E-042.00E-05
GO:0006812Cation transport1416.473.07E-064.990.0021.05E-04
GO:0007155Cell adhesion1416.477.80E-064.580.0062.29E-04

Gene ontology (GO) terms annotation conducted with DAVID classification system (v. 6.7) using a list of proteins (85) identified and quantified in three independent experiments in WT and Fmr1 KO brain DRMs and Mus musculus genome reference background. Selected GO terms for Cellular Components (GOTERM_CC), Molecular Function (GOTERM_MF) and Biological Process (GOTERM_BP) over-represented in genes included in brain raft proteome. Term, GO term description; Count, number of genes annotated with a given term; %, percentage of genes annotated with a given term; P value, significance of gene-term enrichment; Fold enrichment, geometric mean of all the enrichment P values of associated terms; Bonferroni and Benjamini-Hochberg, P-value correction. Redundant or broad GO terms associated with many genes are not listed.

(√), Identified in corresponding proteomic studies: * [58], ** [61], ^ [62], ^^ [60], # [39]. List of all proteins (133) identified in DRMs from adult WT and Fmr1 KO mouse brain. List includes proteins identified in three, two or one experiment. Entry descriptors: UniProtKB, UniProt Knowledgebase database (UniProtKB/Swiss-Prot) Mus musculus protein entry name; gene symbol, Mus musculus; Entrez Gene ID, National Center for Biotechnology Information (NCBI) Entrez Mus musculus gene ID. Columns annotated with symbols (*, **, ^, ^^, #) correspond to proteomic studies listed in appended references that reported identification of the corresponding protein in lipid rafts. List of proteins (85) identified and quantified in three independent experiments in WT and Fmr1 KO brain DRMs. Numbers highlighted in bold correspond to proteins with significantly different abundance in FMR1 KO rafts. Indicated are mean ratio of Fmr1 KO vs. WT (KO/WT), standard deviation (Sdev) and p-value (t-test) in relation to internal reference (HSP7C, mean ± sdev, 1.01 ± 0.064), with p <0.05 considered significant. Entry descriptors: UniProtKB, UniProt Knowledgebase database (UniProtKB/Swiss-Prot) Mus musculus protein entry name; gene symbol, Mus musculus; Entrez Gene ID, National Center for Biotechnology Information (NCBI) Entrez Mus musculus gene ID. Gene ontology (GO) terms annotation conducted with DAVID classification system (v. 6.7) using a list of proteins (85) identified and quantified in three independent experiments in WT and Fmr1 KO brain DRMs and Mus musculus genome reference background. Selected GO terms for Cellular Components (GOTERM_CC), Molecular Function (GOTERM_MF) and Biological Process (GOTERM_BP) over-represented in genes included in brain raft proteome. Term, GO term description; Count, number of genes annotated with a given term; %, percentage of genes annotated with a given term; P value, significance of gene-term enrichment; Fold enrichment, geometric mean of all the enrichment P values of associated terms; Bonferroni and Benjamini-Hochberg, P-value correction. Redundant or broad GO terms associated with many genes are not listed.

Identification of proteins differentially enriched in brain lipid rafts of Fmr1 KO mice

To estimate with a degree of stringency differential raft association of individual protein hits in WT vs. Fmr1 KO mice, we restricted quantitative analysis to those proteins for which high confidence peptides were identified in each of three independent datasets (Table 2). We calculated for each protein a Fmr1 KO/WT ratio, with a ratio of 1 indicating no change and ratios >1 or <1 indicating increased or decreased raft association in Fmr1 KO brain, respectively and compared average ratios to an internal reference protein with ratio ~1 in all experiments. Although the majority of analyzed proteins appeared similarly represented in DRMs from Fmr1 KO vs. WT mice, seven proteins (~8.2% of quantified proteome) displayed statistically significant (mean ± SEM, N = 3, p <0.05) differential abundance (Table 2). Among identified candidates, three showed decreased abundance in Fmr1 KO rafts (Lymphocyte antigen 6H, human locus LY6H, chromosome 8q24.3; Thy-1 membrane glycoprotein, human locus THY1, 11q23.3; CSPG2/Versican core protein, human locus VCAN, 5q14.2) whereas four were increased (ERC protein 2, human locus ERC2, chromosome 3p14.3; Myelin proteolipid protein/Plp1, human locus PLP1, Xq22; Tubulin beta-2A chain, human locus TUBB2A, 6p25.2; Tubulin beta 5 chain, human locus TUBB, 6p21.33). Interestingly, although the lipid raft proteome appeared enriched in proteins encoded by RNA transcripts that are potential FMRP targets [8]- 41 proteins of 133 present in the raft proteome (~31%; Table 4)—only one, Plp1 [8], showed differential abundance in DRMs (~1.2% of 85 quantified proteins).
Table 4

Lipid raft associated proteins in WT and Fmr1 KO brain encoded by FMRP targets.

#Gene symbol
1Actb
2Aldoa
3Atp1a1
4Atp1a3
5Atp1b1
6Atp5a1
7Atp5b
8Atp6v0a1
9Atp6v0d1
10Atp6v1b2
11Bsn
12Calm1
13Camk2a
14Camk2b
15Ckb
16Cltc
17Cnp
18Dlg4
19Dlgap3
20Dpysl2
21Gnao1
22Gnas
23Gnaz
24Gnb1
25Hk1
26Iqsec2
27Mbp
28Myh10
29Myo5a
30Ncam1
31Ncan
32Pclo
33Plp1
34Sept4
35Shank3
36Snap25
37Syngap1
38Syt1
39Tubb3
40Vamp2
41Ywhag

Identified raft proteins that are encoded by RNA transcripts regulated by FMRP, based on a genome-wide HITS-CLIP study in mouse brain [8].

Identified raft proteins that are encoded by RNA transcripts regulated by FMRP, based on a genome-wide HITS-CLIP study in mouse brain [8]. To independently validate changes in association with lipid rafts detected by iTRAQ, we examined the abundance of selected candidate proteins in extracts (Fig 3) or DRMs (Fig 4) from cortex, hippocampus and cerebellum of individual Fmr1 KO and WT mice by Western blot. We focused on candidate proteins (Ly6h, Thy1, Plp1, CSPG2) that displayed more robust changes and for which specific antibodies are available. As control, we also examined the abundance of Homer-1b/c, a scaffold protein that interacts with Gp1 mGluRs [63] and the expression of which was shown to be unaffected in Fmr1 KO mouse brain [64, 65]. We found that expression of Ly6h, Thy-1 and Homer-1b/c did not significantly differ between genotypes in all brain regions examined (Fig 3) but noted a trend to increased abundance of Ly6h in the Fmr1 KO cortex that did not achieve statistical significance (p = 0.1338). In contrast, Plp1 and CSPG2 showed significantly reduced abundance in Fmr1 KO mice in cortex and hippocampus, respectively (Fig 3). Analysis of CSPG2, which is encoded by different splice isoforms, was limited to the V3 form that could be readily detected in our conditions vs. other isoforms of very high molecular mass (>400 kDa). Since Plp1 is a potential FMRP target and alterations in protein levels in Fmr1 KO mice might arise from abnormal translation of mRNAs that bind FMRP, we also examined whether an independent FMRP target—CamKIIα[66, 67]—displayed similarly altered expression and observed no significant difference in Fmr1 KO compared to WT (S1 Fig), in agreement with others [67].
Fig 3

Brain expression of candidate protein hits in Fmr1 KO and WT mice.

A) Representative immunoblots of extracts from cortices, hippocampi and cerebella of Fmr1 KO and WT mice probed with antibodies anti- Homer-1b/c (~ 45 kDa), -Ly6h (~15 kDa), -Plp1 (~ 32 kDa), Thy-1 (~ 25–37 kDa) and CSPG2 (~ 60 kDa). Protein loading was estimated by probing with either anti-TfR1, -γTubulin, -Flotillin or—Gnb2 depending on gel separation. B) Quantification of relative abundance of indicated proteins from experiments like those in (A) measured as ratio of loading control and normalized to WT. Means ± SEM, N = 3 for all groups except Homer-1b/c (cortex), Plp1 and CSPG2 (hippocampus) with N = 4. Unpaired t-test, *p <0.05.

Fig 4

Abundance of candidate protein hits in DRMs of Fmr1 KO and WT mice.

A) Representative immunoblots of combined DRM enriched fractions from individual cortices and cerebella or hippocampi pooled from two animals per group probed with antibodies anti- Homer-1b/c, -Ly6h, -Plp1 or-Thy-1. B) Quantification of relative abundance in DRMs of indicated proteins from experiments like those in (A) normalized to Flotillin content. Calculated KO/WT ratios of candidate proteins were compared to control Flotillin (KO/WT ratio, mean ± SEM 0.997 ± 0.033, N = 3). Means ± SEM, N = 3 for all groups; unpaired t-test, *p <0.05.

Brain expression of candidate protein hits in Fmr1 KO and WT mice.

A) Representative immunoblots of extracts from cortices, hippocampi and cerebella of Fmr1 KO and WT mice probed with antibodies anti- Homer-1b/c (~ 45 kDa), -Ly6h (~15 kDa), -Plp1 (~ 32 kDa), Thy-1 (~ 25–37 kDa) and CSPG2 (~ 60 kDa). Protein loading was estimated by probing with either anti-TfR1, -γTubulin, -Flotillin or—Gnb2 depending on gel separation. B) Quantification of relative abundance of indicated proteins from experiments like those in (A) measured as ratio of loading control and normalized to WT. Means ± SEM, N = 3 for all groups except Homer-1b/c (cortex), Plp1 and CSPG2 (hippocampus) with N = 4. Unpaired t-test, *p <0.05.

Abundance of candidate protein hits in DRMs of Fmr1 KO and WT mice.

A) Representative immunoblots of combined DRM enriched fractions from individual cortices and cerebella or hippocampi pooled from two animals per group probed with antibodies anti- Homer-1b/c, -Ly6h, -Plp1 or-Thy-1. B) Quantification of relative abundance in DRMs of indicated proteins from experiments like those in (A) normalized to Flotillin content. Calculated KO/WT ratios of candidate proteins were compared to control Flotillin (KO/WT ratio, mean ± SEM 0.997 ± 0.033, N = 3). Means ± SEM, N = 3 for all groups; unpaired t-test, *p <0.05. Consistent with quantitative mass spectrometry, we found that Ly6h and Thy-1 abundance in DRMs was significantly reduced in the cortex of Fmr1 KO mice vs. WT (Fig 4) and observed a similar decrease in the hippocampus although in the case of Thy-1 it did not reach statistical significance (KO/WT, p = 0.0664). We further confirmed the presence of Homer-1b/c in lipid raft-enriched membranes with similar abundance in Fmr1 KO and WT mouse cortex and hippocampus (Fig 4). Whereas Ly6h is not expressed in the cerebellum [68], we were unable to estimate Thy-1 and Homer-1b/c abundance in DRMs from cerebellum likely due to low expression in adult animals (Fig 3; [69]). In agreement with proteomic findings, Plp1 showed significantly increased abundance in DRMs from Fmr1 KO cortices (Fig 4) and appeared similarly increased in hippocampus and cerebellum in which though it did not reach statistical significance. CSPG2 expression in DRMs was not examined because the molecular complexity of native Versican (the form detected by mass spectrometry) precluded accurate analysis of high molecular mass isoforms in our experimental conditions. Collectively, these observations suggest that changes in lipid raft composition are not likely to be simply dictated by protein expression levels but may instead also arise from broader cellular dysfunctions in FMRP lacking cells. Biological networks provide a valuable framework to integrate diverse information on protein properties arising from genome-wide proteomic studies and are particularly effective in enabling association of individual proteins/genes to complex functions. To obtain information on molecular networks and pathways that might be affected by abnormalities in lipid rafts, we performed network analysis with GeneMANIA [52] using as query four identified candidate genes: Erc2, Plp1, Thy1 and Vcan. Tubb2a and Tubb5 were omitted from combined analysis because of their broad functionality that could skew network weight, whereas we were unable to integrate Ly6h in pathways analysis due to paucity of molecular information available for this gene. Interestingly, network analysis highlighted connections between identified genes and predicted further functional connectivity with genes encoding components of myelin sheath, axon growth cones (and terminals) and axonal processes (Fig 5). Altogether, our findings could inform prioritization of studies aimed to identify salient molecular and cellular dysfunctions arising from Fmr1 silencing and potentially contribute to uncovering of shared cellular pathologies between FXS and other disorders in the autism spectrum.
Fig 5

Network analysis of selected proteins differentially enriched in brain lipid rafts of Fmr1 KO mice.

Network analysis constructed with GeneMANIA using four (Erc2, Plp1, Thy1, Vcan) of seven identified genes encoding proteins differentially expressed in brain lipid rafts of Fmr1 KO mice. Connections (cellular component based) are predicted based on annotated databases and indicated by links whereby thickness conveys degree of confidence of the relationship. A) Combined network view including four query genes with selected functions highlighted in color: myelin sheath (FDR 1.13e-2), growth cone (FDR 5.89e-4), glial cell migration (FDR 7.41e-2). Additional functions include axon part (FDR 4.17e-4), calcium ion transport ((FDR 8.98e-4), regulation of synaptic transmission (FDR 4.39e-3), positive regulation of lymphocyte activation (FDR 2.2.8e-2). B, C) Network views highlighting neighbours of Thy1 (B) or Plp1 (C).

Network analysis of selected proteins differentially enriched in brain lipid rafts of Fmr1 KO mice.

Network analysis constructed with GeneMANIA using four (Erc2, Plp1, Thy1, Vcan) of seven identified genes encoding proteins differentially expressed in brain lipid rafts of Fmr1 KO mice. Connections (cellular component based) are predicted based on annotated databases and indicated by links whereby thickness conveys degree of confidence of the relationship. A) Combined network view including four query genes with selected functions highlighted in color: myelin sheath (FDR 1.13e-2), growth cone (FDR 5.89e-4), glial cell migration (FDR 7.41e-2). Additional functions include axon part (FDR 4.17e-4), calcium ion transport ((FDR 8.98e-4), regulation of synaptic transmission (FDR 4.39e-3), positive regulation of lymphocyte activation (FDR 2.2.8e-2). B, C) Network views highlighting neighbours of Thy1 (B) or Plp1 (C).

Discussion

Here, we used an unbiased, genome-wide proteomic strategy to define the brain lipid raft proteome of Fmr1 knockout mice—an animal model of Fragile X syndrome—and test the hypothesis that raft association of subsets of proteins might be affected by homeostatic changes occurring in absence of FMRP. We found that whereas overall proteome representation (~93%) is conserved, a discrete subset of proteins displays significantly altered abundance in DRMs of Fmr1 KO mice. Gene ontology and network analysis of proteins displaying abnormal abundance in absence of FMRP suggest convergence onto common cellular components and biological processes, such as axonal processes and myelination, emphasizing novel aspects of the complex biology of Fragile X syndrome and potentially other disorders in the autism spectrum. The raft proteome shows an estimated maximum complexity of approximately 200 proteins based on studies carried out with different technologies and biological samples including HeLa cells [59], neonatal mouse brain [58] and human brain tissue [62]. Results from our study applying stringent criteria for protein assignment, identify 133 proteins in lipid-raft enriched membrane fractions of adult mouse brain, consistent with expected raft proteome complexity, and illustrate robust proteome coverage by iTRAQ despite incomplete peptide overlap among experiments that precluded quantitative analysis of all identified proteins. Observed variance in relative protein abundance reported by iTRAQ was modest (highest ratio difference ~1.5-fold, lowest ~0.6-fold) but of magnitude consistent with biologically relevant differences. Although iTRAQ offers a high degree of precision, it does not provide a measure of ‘absolute’ changes in protein abundance [47]: moreover, ratio compression can also arise from the fact that DRMs are a complex heterogeneous mixture of membranes extracted from different brain regions and cell types with potentially different properties. We found that approximately 48% of the raft proteome, for which we could apply quantitation, is encoded by FMRP mRNA targets. Surprisingly, although absence of FMRP can lead to enhanced mRNA translation we found that only one identified FMRP target shows significantly increased abundance in DRMs of Fmr1 KO mice. Several mRNA targets of FMRP [8] encode proteins involved in lipid homeostasis, including lipid synthesis (e.g. PIGQ, FASN, SCD2, AGPAT3), metabolism (e.g. LPIN2, LPPR4, CPT1A, SMPD3), and cholesterol homeostasis (e.g. SREBF2, SCAP) and transport (e.g. LPR1, SORL1, ABCA3, LRP8). For example, PIGQ is involved in early steps of GPI anchor biosynthesis [70] and deficiencies in this pathway are linked to Mabry syndrome [71] marked by severe developmental delays and intellectual disability, autosomal recessive intellectual disability [72] and intractable epilepsy [73]. Notably, two GPI-linked proteins—Thy-1 and Ly6h —display altered abundance in Fmr1 KO rafts, suggesting the possibility that GPI biosynthesis may be compromised in absence of FMRP. Involvement of potential dysfunctions in lipid homeostasis in FXS is further suggested by the findings that HMG-CoA reductase inhibitors that reduce cholesterol synthesis partly correct pathological dysfunctions in Fmr1 KO mice [74] and decrease Gp1 mGluR signaling to ERK1/2 in Fmr1 KO null neurons [57], lending indirect support for a potential role of the cholesterol biosynthetic pathway in FXS manifestations, at least in animal models. An interesting observation arising from quantitative proteomics is that whereas a subset of proteins showed increased abundance in DRMs of Fmr1 KO mice, a group of proteins including Thy-1 and Ly6h displayed decreased raft association. Thy-1 is a developmentally regulated IgG-like protein enriched in neurons [75]. Although its precise functions and mechanisms of action remain unclear, Thy-1 was shown to inhibit neurite outgrowth and stabilize neuronal processes [76] via both cis- and trans-interactions between neuronal Thy-1 and αVβ3 integrin in astrocytes, a mechanism contributing to Thy-1 impact on neurite outgrowth [77]. Importantly, lipid raft integrity and intact GPI anchor are required for Thy-1 actions. Thy1 knockout mice show impaired LTP in dentate gyrus [78] and behavioral abnormalities such as impaired social transmission of food preference [79] that are consistent with a critical function for this locus in neurodevelopment and neurodevelopmental disorders [80]. Ly6h, a GPI-anchored protein, is a member of the Ly6 complex—a protein family involved in immune regulation—encoded by ≥ 20 genes many of which cluster in human chromosome 8q24.3, a hot spot of deletion/duplication events linked to ASD and attention deficit hyperactivity disorder [81]. Ly6h expression in neurons is developmentally regulated and spatially restricted to specific brain regions (e.g. frontal cortex, hippocampus [68]). Although its function in the brain is unknown, the closely related Ly6/Neurotoxin 1 (Lynx1) was shown to modulate nAChRs functional properties and stabilize mature cortical networks [82]. Interestingly, peptides corresponding to Lynx1 were identified in DRMs by our study but not included in proteome data analysis on quality grounds. Outside the CNS, both Ly6h and Thy-1 are expressed in immune related cells including human cortical thymocytes and lymphoblastoid cell lines, suggesting the possibility that they could represent novel biomarkers for FXS and potentially other ASDs. In addition to GPI-linked proteins, another protein showing decreases raft association in Fmr1 KO mice is the versican core protein CSPG2/Vcan, a proteoglycan and a major component of extracellular matrix, with functions in cells adhesion and presynaptic maturation [83] among others. Several proteins displayed increased abundance in brain rafts from Fmr1 KO mice, most prominently Plp1, an abundant component of CNS myelin, which plays a critical function in myelin formation and maintenance, oligodendrocyte development and axonal survival [84]. Mutations in PLP1 are linked to Pelizaeus-Merzbacher disease and spastic paraplegia (SPG2), conditions associated with intellectual disability and ASD [85]. Proteomic profiling also identified other protein components of the myelin sheath including CNP, MBP, MOBP and MOG all of which displayed a trend (not statistically significant) to increased abundance in Fmr1 KO rafts (Table 2). Consistent with this, network analysis highlights myelin sheath as a potential convergent pathway for identified protein with abnormal abundance in Fmr1 KO rafts. Myelination abnormalities are detected in FXS patients [86] and recent evidence indicates that FMRP is expressed in oligodendrocytes [87] and Fmr1 KO mice display delayed myelination during development [88]. Together, these observations suggest that dysfunctions of myelination at the cellular and/or circuitry level may play an important and unappreciated role in pathological manifestations of FXS. An additional subset of proteins also appeared to be modestly increased in rafts from mutant Fmr1 mice including two tubulin beta chain isoforms, encoded by Tubb5 and Tubb2a respectively, and ERC2. Tubulin has been shown to associate with lipid rafts and disruption of the microtubule cytoskeleton can lead to remodeling of raft membrane composition [53]. ERC2 is enriched at the presynaptic active zone and implicated in organization of the cytomatrix at synaptic terminals [89]: interestingly, the closely related ERC1 is associated with ASD [90]. The precise mechanisms underlying altered raft association in Fmr1 KO mice are at present unclear and they could involve changes in overall protein abundance or abnormalities in protein trafficking. Moreover, since DRMs are a heterogeneous mixture of membranes they do not allow to distinguish whether observed changes occur in defined cell populations and whether they are cell-autonomous or dependent on cell adhesion or trophic conditions in intact circuitry. Use of orthogonal strategies will be needed in the future to address these questions and further determine whether abnormalities in raft association reflect homeostatic adaptation in the adult brain (used in this study) and/or are present at early stages of brain development.

Brain expression of CaMKIIα/β in Fmr1 KO and WT mice.

A) Representative immunoblots of cortical extracts from WT and Fmr1 KO mice probed with anti-CaMKIIα/β and pan-β Tubulin antibodies. B) Quantification of CaMKIIα/β relative abundance from experiments like those in (A) measured as ratio of band densities for CaMKIIα/β vs. tubulin and normalized to WT: means ± SEM, N = 3, unpaired t-test, p = 0.157 and p = 0.203 for CaMKIIαand CaMKIIβ respectively. (TIF) Click here for additional data file.

List of peptides identified in WT and Fmr1 KO mouse brain.

Number of peptide matches and corresponding protein identified in three (A) two (B) or one (C) experiment. Columns E1-3 indicate number of peptide matches obtained for each protein hit: numbers in brackets indicate number of peptide used for ratio when calculated. (XLS) Click here for additional data file.
  90 in total

1.  12p13.33 microdeletion including ELKS/ERC1, a new locus associated with childhood apraxia of speech.

Authors:  Julien Thevenon; Patrick Callier; Joris Andrieux; Bruno Delobel; Albert David; Sylvie Sukno; Delphine Minot; Laure Mosca Anne; Nathalie Marle; Damien Sanlaville; Marlène Bonnet; Alice Masurel-Paulet; Fabienne Levy; Lorraine Gaunt; Sandra Farrell; Cédric Le Caignec; Annick Toutain; Virginie Carmignac; Francine Mugneret; Jill Clayton-Smith; Christel Thauvin-Robinet; Laurence Faivre
Journal:  Eur J Hum Genet       Date:  2012-06-20       Impact factor: 4.246

Review 2.  Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.

Authors:  Gary J Bassell; Stephen T Warren
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

3.  High recovery HPLC separation of lipid rafts for membrane proteome analysis.

Authors:  James Martosella; Nina Zolotarjova; Hongbin Liu; Susanne C Moyer; Patrick D Perkins; Barry E Boyes
Journal:  J Proteome Res       Date:  2006-06       Impact factor: 4.466

Review 4.  Disentangling the heterogeneity of autism spectrum disorder through genetic findings.

Authors:  Shafali S Jeste; Daniel H Geschwind
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

5.  Identification of GPCR localization in detergent resistant membranes.

Authors:  Ranju Kumari; Anna Francesconi
Journal:  Methods Mol Biol       Date:  2011

Review 6.  Greasing their way: lipid modifications determine protein association with membrane rafts.

Authors:  Ilya Levental; Michal Grzybek; Kai Simons
Journal:  Biochemistry       Date:  2010-08-03       Impact factor: 3.162

7.  Versican in the developing brain: lamina-specific expression in interneuronal subsets and role in presynaptic maturation.

Authors:  Masahito Yamagata; Joshua R Sanes
Journal:  J Neurosci       Date:  2005-09-14       Impact factor: 6.167

8.  Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains.

Authors:  Marie Molander-Melin; Kaj Blennow; Nenad Bogdanovic; Birgitta Dellheden; Jan-Eric Månsson; Pam Fredman
Journal:  J Neurochem       Date:  2005-01       Impact factor: 5.372

Review 9.  Fragile X Syndrome: from molecular pathology to therapy.

Authors:  Thomas Maurin; Samantha Zongaro; Barbara Bardoni
Journal:  Neurosci Biobehav Rev       Date:  2014-01-22       Impact factor: 8.989

Review 10.  Lipid rafts, cholesterol, and the brain.

Authors:  Zeljka Korade; Anne K Kenworthy
Journal:  Neuropharmacology       Date:  2008-03-14       Impact factor: 5.250

View more
  6 in total

Review 1.  Glial Contributions to Neural Function and Disease.

Authors:  Matthew N Rasband
Journal:  Mol Cell Proteomics       Date:  2015-09-04       Impact factor: 5.911

2.  Antidepressants Accumulate in Lipid Rafts Independent of Monoamine Transporters to Modulate Redistribution of the G Protein, Gαs.

Authors:  Samuel J Erb; Jeffrey M Schappi; Mark M Rasenick
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 3.  The role of cholesterol metabolism and various steroid abnormalities in autism spectrum disorders: A hypothesis paper.

Authors:  Christopher Gillberg; Elisabeth Fernell; Eva Kočovská; Helen Minnis; Thomas Bourgeron; Lucy Thompson; Clare S Allely
Journal:  Autism Res       Date:  2017-04-12       Impact factor: 5.216

4.  Of Men and Mice: Modeling the Fragile X Syndrome.

Authors:  Regina Dahlhaus
Journal:  Front Mol Neurosci       Date:  2018-03-15       Impact factor: 5.639

5.  Na/K-ATPase beta1-subunit associates with neuronal growth regulator 1 (NEGR1) to participate in intercellular interactions.

Authors:  Yeongmi Cheon; Ara Yoo; Hyunseok Seo; Seo-Young Yun; Hyeonhee Lee; Heeji Lim; Youngho Kim; Lihua Che; Soojin Lee
Journal:  BMB Rep       Date:  2021-03       Impact factor: 4.778

6.  Brain Cholesterol Biosynthetic Pathway Is Altered in a Preclinical Model of Fragile X Syndrome.

Authors:  Martina Parente; Claudia Tonini; Valeria Buzzelli; Emilia Carbone; Viviana Trezza; Valentina Pallottini
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.